Synchronous Primary Adenocarcinoma of the Lung and Pancreas: A Case Series and Review of the Literature

Puri, Akshjot; Ma, Li; Walker, Gary V.; Chang, J W; Shinar, Ron Z; Kundranda, Madappa N.

doi:10.2217/lmt-2017-0003

Cited by 4 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite recent advances in the field of oncology, PDAC remains a rapidly fatal disease. Although definite causes of PDAC are yet to be identified, there are known risk factors precluding to a higher probability, such as chronic pancreatitis, increasing age, obesity, smoking, race, family history, genetic predisposition, and environmental factors [8].…”

Section: Discussionmentioning

confidence: 99%

A Rare Double Primary Tumor of the Pancreas and the Esophagus

Satiya

Girotra

2019

Cureus

View full text Add to dashboard Cite

Primary pancreatic cancer with synchronous primary tumors from other organs is extremely rare. Hereditary conditions, such as Lynch syndrome, Peutz-Jeghers syndrome, and hereditary pancreatitis, are linked to 10% of pancreatic cancers and may increase the risk of secondary malignancies from other organs. Only three cases of synchronous cancers of the pancreas and esophagus have been reported in the literature. Interestingly, patients with double primary tumors have been observed to have better overall survival than those with pancreatic cancers alone. We report the fourth such case of a 54-year-old male diagnosed with a double primary cancer of the pancreas and the esophagus diagnosed with endoscopic ultrasound (EUS).

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Double Primary Tumor of the Pancreas and the Esophagus

Satiya

Girotra

2019

Cureus

View full text Add to dashboard Cite

show abstract

“… 1 Synchronous NSCLC and ductal adenocarcinoma of the pancreas is also very uncommon. 2 Patients with locally advanced, non-operable or metastatic NSCLC may be treated with palliative intent systemic therapy and radiation. Immune checkpoint inhibitor (ICI) therapy as a single agent is a first-line treatment option for NSCLC patients whose tumors do not harbor an activating mutation or fusion, especially in tumors with a programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) tumor proportion score (TPS) of ⩾50%.…”

Section: Introductionmentioning

confidence: 99%

Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab

Saltman

Nielsen²,

Salina

et al. 2021

Ther Adv Med Oncol

View full text Add to dashboard Cite

Single-agent immune checkpoint inhibitor therapy in advanced non-small cell lung cancer can significantly prolong progression-free and overall survival when compared with cytotoxic chemotherapy. Here, we report a case of newly diagnosed adenocarcinoma of the lung with a solitary brain metastasis and a biopsy confirmed adenocarcinoma in the tail of the pancreas. Cytomorphology and immunohistochemistry suggested the lung and pancreas tumors were distinct primaries. However, molecular analysis of the lung primary and tumor in the pancreas revealed the same mutations of functional significance in PIK3CA, NF1 and TP53, suggesting the tumors were clonal. A total of three cycles of single-agent pembrolizumab, and radiation to the lung and brain administered between cycles 1 and 2, resulted in marked responses in lung, brain and pancreatic tumors. Despite the discontinuation of the pembrolizumab after three cycles due to severe immune-mediated toxicities, the patient has had no progression 11 months after stopping all active treatment. Results of a novel 27-gene immuno-oncology (IO) expression assay revealed strong IO scores for the lung and pancreatic tumors, indicating a favorable tumor immune-microenvironment and possibly explaining the significant response.

show abstract

“…3 4 Common factors such as a strong smoking history, dietary factors, comorbidities, genetics and chronic inflammation may contribute to some extent to the development of synchronous malignancies as well. 5 …”

Section: Introductionmentioning

confidence: 99%

Multiple primary malignancies: synchronous lymphoma, pancreatic neuroendocrine tumour and colorectal cancer

et al. 2021

View full text Add to dashboard Cite

A 67-year-old woman underwent a medical check-up by her general practitioner after complaining of atypical pain in the shoulder girdle. Due to the important inflammatory syndrome noticed on blood testing, a polymyalgia rheumatica was suspected and she was started on corticosteroid treatment with good clinical response, but no impact on inflammation. She underwent extensive imaging with a thoraco-abdominal CT scanner that demonstrated a pancreatic mass, then later a PET-CT showed 3 different hyperactive lesions. Biopsies then revealed simultaneous diffuse large B-cell lymphoma (DLBCL), colorectal adenocarcinoma and pancreatic neuroendocrine tumour. She benefited from low rectal endoscopic excision of the colorectal tumour, R-CHOP chemotherapy for DLBCL and laparoscopic left pancreatectomy. Successful treatment required a good multidisciplinary collaboration between the different specialists. The patient made a good recovery and achieved complete remission at 1 year. This an unusual presentation of multiple primary malignancies.

show abstract

Synchronous Primary Adenocarcinoma of the Lung and Pancreas: A Case Series and Review of the Literature

Cited by 4 publications

References 12 publications

A Rare Double Primary Tumor of the Pancreas and the Esophagus

A Rare Double Primary Tumor of the Pancreas and the Esophagus

Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab

Multiple primary malignancies: synchronous lymphoma, pancreatic neuroendocrine tumour and colorectal cancer

Contact Info

Product

Resources

About